

## Carlyle, Viyash Life Sciences build generic pharma platform in India

16 November 2021 | News

**Carlyle commenced its partnership with Viyash in June 2021 when the company acquired a controlling stake in Symed Labs**



Global investment firm Carlyle and seasoned pharmaceutical professionals Dr Hari Babu and Dr Srihari Raju Kalidindi, founder and co-founder of Hyderabad-based Viyash Life Sciences have announced that CA Hull Investments, an affiliated entity of CAP V Mauritius and Carlyle (collectively, Carlyle) and Viyash have established an integrated generic pharmaceutical platform in India.

Viyash has ten manufacturing facilities in India with a combined capacity of ~2000 KL as well as one formulation facility in the US. The majority of the sites are US FDA approved for API or Intermediates and are capable of servicing both regulated and semi-regulated markets.

In the future, Viyash intends to seek further investment opportunities to build scale by targeting acquisitions with niche differentiated capabilities that complement the existing operations of the platform. It will focus on both regulated and emerging markets for generics supply.

Dr Hari commented, “Viyash will focus on providing global formulation players with end to end manufacturing capabilities. Our next phase will be to drive further integration and growth opportunities across the three businesses.”

“Carlyle’s global healthcare expertise and network of portfolio companies, coupled with our industry knowledge and experience, will help us create significant value for the platform,” added Dr Srihari.